NeXtGen™ Biologics Secures Favorable Outcome in Inter-Partes Patent Review (BioSpace)
UF Innovate | Accelerate resident client NeXtGen Biologics reported that the U.S. Patent and Trademark Office declined to initiate an inter partes review of its wound care patents, leaving the intellectual property fully enforceable.
NeXtGen Biologics Successfully Completes First FDA Audit With Zero 483 Observations (Globe Newswire)
UF Innovate | Accelerate resident client NeXtGen Biologics announced the successful completion of a two-day inspection by the U.S. Food and Drug Administration (FDA).